Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial

HIMRT is more cost-efficient than CIMRT for treating prostate cancer, even when taking into account the costs related to late radiation toxicities. HIMRT enhances the value of prostate radiation when compared with CIMRT.